Summary
353 adult patients aged from 26 to 90 years with complicated urinary tract infections were investigated in a double-blind randomised multicentre trial in which 176 patients received cefetamet pivoxil (CAT) 500mg twice daily and 177 patients cefuroxime axetil (CMX) 250mg twice daily for 7 days. The groups were comparable. The bacteriological findings that were evaluated 7 to 10 days post-therapy were the main criteria for assessment of efficacy. Patients were followed up for 5 ± 1 weeks post-therapy. Bacteriological assessment was possible in 310 patients, i.e. 156 patients from the CAT group and 154 from the CMX group. Escherichia coli proved to be the predominant causative pathogen in this patient series, occurring in 68.4%. The overall bacteriological outcome was successful in 97.4% of the patients receiving CAT and 90.3% to whom CMX was given. The pathogens persisting in the CAT group were E. coli (1), Proteus rettgeri (1), and Klebsiella pneumoniae (1), while in the CMX group the pathogens were E. coli (4), Proteus spp. (2), K. pneumoniae (1), Enterobacter sp. (1), Serratia sp. (1), Levinia sp. (1) and mixed infection (1). The overall clinical outcome was successful in 137 (87.8%) of 156 assessable patients treated with CAT and in 129 (83.8%) of 154 patients to whom CMX was administered. The incidence of adverse events was 11.9% in both treatment groups. All adverse events were mild to moderate in severity and predominantly gastrointestinal. Treatment was withdrawn prematurely in 1 patient receiving CMX because of rash. Based on the presented data, we conclude that cefetamet pivoxil in the recommended dosage of 500mg twice daily is effective and well tolerated in the treatment of patients with complicated urinary tract infections.
Similar content being viewed by others
References
Bryson HM, Brogden RN. Cefetamet pivoxil: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 45: 589–621, 1993
Cullmann W, Edwards DJ, Kissling M, Kneer J, Stoeckel K, et al. Cefetamet pivoxil: a review of its microbiology, toxicology, pharmacokinetics and clinical efficacy. International Journal of Antimicrobial Agents 1: 175–192, 1992
Cullmann W, Then RLF. Cefetamet: its in vitro activity and interaction with β-lactamase and penicillin-binding proteins. Drug Investigation 3: 299–307, 1991
Goldstein F, Kitzis MD, Gutmann L, Accar JF. Comparative activity of oral cephalosporins against β-lactamase producing pathogens. Médecine et Maladies Infectieuses 22: 535–543, 1992
Gonzalez JP, Henwood JM. Pefloxacin. A review of its antibacterial activity. Pharmacokinetic properties and therapeutic use. Drugs 37: 628–668, 1989
Kissling M. Cefetamet pivoxil: a review of clinical experience. Médecine et Maladies Infectieuses 22: 565–575, 1992
Kissling M, Chadbourne U. Literature survey on clinical efficacy and tolerability of cefetamet pivoxil: an analysis of 3,128 cases. Respiration 60 (Suppl. 1): 45–54, 1993
Kitzis MD, Liassine N, Ferre B, Gutmann L, Acar JF. In vitro activities of 15 oral β-lactams against Klebsiella pneumoniae harboring new extended-spectrum β-lactamases. Antimicrobial Agents and Chemotherapy 34: 1783–1786, 1990
National Committee for Clinical Laboratory Standards. NCCLS document M7-A2 12, 1992
National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests — fourth edition. NCCLS document M2-A4 10, 1990
Stoeckel K. Pharmacokinetics of intravenous cefetamet and oral cefetamet pivoxil in human subjects. Drug Investigation 3: 291–298, 1991
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Vieiralves, L.F.A., Lucena, R., Borges, C.H. et al. Comparative Study of Cefetamet Pivoxil and Cefuroxime Axetil in Complicated Urinary Tract Infections. Drug Invest. 6, 347–352 (1993). https://doi.org/10.1007/BF03259611
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03259611